Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased TRPM7 expression was associated with enhanced SOX2, KLF4, and CD133, Hsp90α, uPA, and MMP2 expression in lung cancer cells.
|
30477473 |
2018 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quercetin metabolites inhibit MMP-2 expression in A549 lung cancer cells by PPAR-γ associated mechanisms.
|
27260467 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
And the lung cancer metastasis factors (MMP-2, MMP-9, VEGF, and CXCR4) were decreased in miR-451 group by Western blot.
|
25150396 |
2015 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggested that PFIO could suppress the invasion and migration of human lung carcinoma by reducing the expression levels and activity of MMP-2 and MMP-9 via suppression of MAPKs, PI3K/AKT, and NF-κB signaling pathways.
|
25270791 |
2014 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also showed that HMGB1 promoted lung cancer invasion and metastasis by upregulating the expression and activity of MMP-2 in an NF-<i>κ</i>B-dependent manner.
|
29850505 |
2018 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transcriptional analysis also revealed that lnc-MMP2-2 was highly enriched in TGF-β-mediated exosomes and might function by increasing the expression of matrix metalloproteinase (MMP)2 through its enhancer activity, with ectopic expression and silencing of lnc-MMP2-2 affecting lung cancer invasion and vascular permeability.
|
30256540 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The levels of latent and active forms of MMP-2 in lung cancer samples were, correspondingly, 3.8- and 17-fold higher than in lung parenchyma.
|
11935310 |
2002 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the decrease of MMP-2/-9 expression on lung cancer cell lines was associated with AQP1-siRNA doses.
|
26151179 |
2015 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MMP-2(1306C-->T) (OR, 0.53; 95% CI, 0.40-0.72; p < 0.0001) and 735(C-->T) (OR, 0.65; 95% CI, 0.53-0.79; p < 0.0001) were significantly associated with protection against lung cancer.
|
19507256 |
2009 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Subgroup by study design, ethnicity and testing methods all further identified the prognostic value of MMP2 expression in lung cancer.
|
22718017 |
2012 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TOB1 also regulates the gelatinase activity of MMP2 and MMP9 in lung cancer cells.
|
22158108 |
2012 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These observations indicate that hinokitiol inhibited the migration of lung cancer A549 cells through several mechanisms, including the activation of caspases-9 and -3, induction of p53/Bax and antioxidant CAT and SOD, and reduction of MMP-2 and -9 activities.
|
29565268 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to previous findings, matrix metalloproteinase-2 (MMP-2) is closely correlated with metastatic potential in lung cancer.
|
22082235 |
2011 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Decreases in the MMP-2 (-735) polymorphism GG genotype and increases in the MMP-13 (A77G) polymorphism AG and GG genotypes increase the risk for lung cancer.
|
23465389 |
2013 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we demonstrated that Capn4 enhanced the invasion ability of lung cancer cells by upregulating the expression of matrix metalloproteinase 2.
|
25636510 |
2015 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The positive expression of p53 and MMP-2 in lung cancer tissues before chemotherapy was 76.25 and 71.25%, respectively, and were reduced to 27.50 and 23.75%, respectively, after chemotherapy.
|
30214563 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS The putative mechanism behind the metastasis-limiting effects of DHC may involve the suppression of Akt/GSK-3β and inhibition of MMP-2 and MMP-9 in lung cancer cells.
|
30388099 |
2018 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A higher MMP-2 activity was detected in lung cancer group in comparison with benign and control groups.
|
24415566 |
2014 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations indicated that naringenin inhibited the migration of lung cancer A549 cells through several mechanisms, including the inhibition of AKT activities and reduction of MMP-2 and -9 activities.
|
28352360 |
2017 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MMP2 genotypes and haplotypes were determined in 770 cases and 777 controls and the associations with risk of lung cancer were estimated by logistic regression.
|
15731163 |
2005 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this work, we report a facile approach of the fabrication of gold nanostars (GNS) attached with matrix metalloproteinases (MMP2) polypeptides (Ac-GPLGIAGQ) and IR-780 iodide through bovine serum albumin (BSA) for targeted dual-modal photoacoustic (PA)/near-infrared (NIR) fluorescence imaging and enhanced photothermal therapy (PTT)/photodynamic therapy (PDT) for lung cancer.
|
30851455 |
2019 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we claimed that determining of MMP-2 enzyme level can be used as a marker in lung cancer.
|
20845079 |
2011 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results showed that under dominant genetic model, MMP2 -1306 T was associated with lower susceptibility to lung cancer [odds ratio (OR) = 0.50, 95% confidence interval (CI) 0.43-0.59, P(heterogeneity) = 0.147, I(2) = 44.1%], head and neck cancer (OR = 0.53, 95% CI 0.41-0.69, P(heterogeneity) = 0.974, I(2) = 0.0%) and oesophageal cancer (OR = 0.67, 95% CI 0.55-0.80, P(heterogeneity) = 0.593, I(2) = 0.0%); MMP2-735T was associated with lower risk in lung cancer (OR = 0.65, 95%CI 0.53-0.79, P(heterogeneity) = 0.42, I(2) = 0.0%) and oesophageal cancer (OR = 0.84, 95% CI 0.70-0.99, P(heterogeneity) = 0.206, I(2) = 37.4%); MMP7 -181 AG and GG genotype carriers had an increased gastric cancer risk (OR = 1.90, 95% CI 1.43-2.51, P(heterogeneity) = 0.992, I(2) = 0.0%) and MMP9 -1562 C>T was not associated with cancer risk in the whole group analysis (OR = 0.99, 95% CI 0.91-1.08, P(heterogeneity) = 0.419, I(2) = 3.0%) and subgroup analyses.
|
20360147 |
2010 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanistically, linc00858 acted as a competitive endogenous RNA to sponged miR-3182 and regulate MMP2 in lung cancer.
|
31131637 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Measurement of MMP-2 and TIMP-2 in BALF might be helpful for differential diagnosis of primary lung cancer.
|
29113325 |
2017 |